February 7, 2018 / 9:24 AM / 5 months ago

BRIEF-GSK Says Bexsero Gets Breakthrough Therapy Designation From U.S. FDA​

Feb 7 (Reuters) - Glaxosmithkline Plc:

* GSK’S BEXSERO FDA BREAKTHROUGH THERAPY DESIGNATION

* GSK-BEXSERO GETS BREAKTHROUGH THERAPY DESIGNATION FROM FDA FOR PREVENTION OF INVASIVE MENINGOCOCCAL DISEASE IN CHILDREN AGED 2-10 YRS ​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below